FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014748618> ?p ?o ?g. }

• W2014748618 endingPage "112C" @default.
• W2014748618 startingPage "107C" @default.
• W2014748618 abstract "The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study was designed when considerable disagreement existed as to relative benefits and risks of cholesterol reduction. Between June 1990 and December 1992, 9,014 patients aged 31–75 years were randomized to receive either pravastatin 40 mg once daily or placebo. These patients had experienced either acute myocardial infarction or unstable angina within the preceding 3 months to 3 years and had total cholesterol levels of 155–271 mg/dl (4.0–7.0 mmol/liter). All patients received dietary advice. The LIPID study is projected for conclusion in 1997, after a follow-up period of at least 5 years. The primary study endpoint is mortality due to coronary artery disease (CAD). The Scandinavian Simvastatin Survival Study (4S) is the first secondary prevention trial to show a reduction in total mortality with lipid-lowering therapy. However, the LIPID study should continue for the following reasons: (1) important differences exist between the LIPID study and 4S cohorts. Overall, >80% of the LIPID patients could not have been included in 4S on the basis of their cholesterol level, age, or history of CAD; (2) the LIPID study will also provide important information on noncoronary mortality and on other groups, such as women and diabetic patients, who have been underrepresented in previous trials; (3) the LIPID study design allows for clinical management, including lipid-lowering therapy, to be at the discretion of the physician managing a trial patient. The 4S results have been brought to the attention of all LIPID investigators, Institutional Ethics Committees, the physicians of the individual patients, and the patients themselves. After reviewing 4S results, any physician who is convinced of the benefits of cholesterol-lowering therapy for a particular patient can commence active treatment; (4) revised power calculations, including assumptions that the number of drop-in patients will increase even up to 40%, with only 1% reduction in deaths due to CAD for each 1% reduction in the level of total cholesterol, show that the LIPID study is still scientifically viable. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study was designed when considerable disagreement existed as to relative benefits and risks of cholesterol reduction. Between June 1990 and December 1992, 9,014 patients aged 31–75 years were randomized to receive either pravastatin 40 mg once daily or placebo. These patients had experienced either acute myocardial infarction or unstable angina within the preceding 3 months to 3 years and had total cholesterol levels of 155–271 mg/dl (4.0–7.0 mmol/liter). All patients received dietary advice. The LIPID study is projected for conclusion in 1997, after a follow-up period of at least 5 years. The primary study endpoint is mortality due to coronary artery disease (CAD). The Scandinavian Simvastatin Survival Study (4S) is the first secondary prevention trial to show a reduction in total mortality with lipid-lowering therapy. However, the LIPID study should continue for the following reasons: (1) important differences exist between the LIPID study and 4S cohorts. Overall, >80% of the LIPID patients could not have been included in 4S on the basis of their cholesterol level, age, or history of CAD; (2) the LIPID study will also provide important information on noncoronary mortality and on other groups, such as women and diabetic patients, who have been underrepresented in previous trials; (3) the LIPID study design allows for clinical management, including lipid-lowering therapy, to be at the discretion of the physician managing a trial patient. The 4S results have been brought to the attention of all LIPID investigators, Institutional Ethics Committees, the physicians of the individual patients, and the patients themselves. After reviewing 4S results, any physician who is convinced of the benefits of cholesterol-lowering therapy for a particular patient can commence active treatment; (4) revised power calculations, including assumptions that the number of drop-in patients will increase even up to 40%, with only 1% reduction in deaths due to CAD for each 1% reduction in the level of total cholesterol, show that the LIPID study is still scientifically viable." @default.
• W2014748618 created "2016-06-24" @default.
• W2014748618 creator A5033034869 @default.
• W2014748618 date "1995-09-01" @default.
• W2014748618 modified "2023-09-27" @default.
• W2014748618 title "Management of the long-term intervention with pravastatin in ischaemic disease (LIPID) study after the scandinavian simvastatin survival study (4S)" @default.
• W2014748618 cites W1548990295 @default.
• W2014748618 cites W1549654956 @default.
• W2014748618 cites W1927300786 @default.
• W2014748618 cites W1965623938 @default.
• W2014748618 cites W1984058728 @default.
• W2014748618 cites W1987876724 @default.
• W2014748618 cites W1994076669 @default.
• W2014748618 cites W1996447072 @default.
• W2014748618 cites W1998616342 @default.
• W2014748618 cites W2017589947 @default.
• W2014748618 cites W2022109882 @default.
• W2014748618 cites W2024674799 @default.
• W2014748618 cites W2026856116 @default.
• W2014748618 cites W2031202586 @default.
• W2014748618 cites W2069297972 @default.
• W2014748618 cites W2072658738 @default.
• W2014748618 cites W2083775127 @default.
• W2014748618 cites W2086705478 @default.
• W2014748618 cites W2089900480 @default.
• W2014748618 cites W2125967584 @default.
• W2014748618 cites W2132931461 @default.
• W2014748618 cites W2324712847 @default.
• W2014748618 cites W2335979330 @default.
• W2014748618 cites W2398194252 @default.
• W2014748618 cites W2407060078 @default.
• W2014748618 cites W2463307031 @default.
• W2014748618 doi "https://doi.org/10.1016/s0002-9149(99)80479-2" @default.
• W2014748618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7572678" @default.
• W2014748618 hasPublicationYear "1995" @default.
• W2014748618 type Work @default.
• W2014748618 sameAs 2014748618 @default.
• W2014748618 citedByCount "42" @default.
• W2014748618 countsByYear W20147486182012 @default.
• W2014748618 countsByYear W20147486182014 @default.
• W2014748618 countsByYear W20147486182015 @default.
• W2014748618 countsByYear W20147486182016 @default.
• W2014748618 countsByYear W20147486182018 @default.
• W2014748618 crossrefType "journal-article" @default.
• W2014748618 hasAuthorship W2014748618A5033034869 @default.
• W2014748618 hasConcept C126322002 @default.
• W2014748618 hasConcept C142724271 @default.
• W2014748618 hasConcept C164705383 @default.
• W2014748618 hasConcept C168563851 @default.
• W2014748618 hasConcept C203092338 @default.
• W2014748618 hasConcept C204787440 @default.
• W2014748618 hasConcept C27081682 @default.
• W2014748618 hasConcept C2776329913 @default.
• W2014748618 hasConcept C2777628954 @default.
• W2014748618 hasConcept C2778096610 @default.
• W2014748618 hasConcept C2778163477 @default.
• W2014748618 hasConcept C2778213512 @default.
• W2014748618 hasConcept C2778270857 @default.
• W2014748618 hasConcept C2778425758 @default.
• W2014748618 hasConcept C2779134260 @default.
• W2014748618 hasConcept C2779519902 @default.
• W2014748618 hasConcept C500558357 @default.
• W2014748618 hasConcept C71924100 @default.
• W2014748618 hasConceptScore W2014748618C126322002 @default.
• W2014748618 hasConceptScore W2014748618C142724271 @default.
• W2014748618 hasConceptScore W2014748618C164705383 @default.
• W2014748618 hasConceptScore W2014748618C168563851 @default.
• W2014748618 hasConceptScore W2014748618C203092338 @default.
• W2014748618 hasConceptScore W2014748618C204787440 @default.
• W2014748618 hasConceptScore W2014748618C27081682 @default.
• W2014748618 hasConceptScore W2014748618C2776329913 @default.
• W2014748618 hasConceptScore W2014748618C2777628954 @default.
• W2014748618 hasConceptScore W2014748618C2778096610 @default.
• W2014748618 hasConceptScore W2014748618C2778163477 @default.
• W2014748618 hasConceptScore W2014748618C2778213512 @default.
• W2014748618 hasConceptScore W2014748618C2778270857 @default.
• W2014748618 hasConceptScore W2014748618C2778425758 @default.
• W2014748618 hasConceptScore W2014748618C2779134260 @default.
• W2014748618 hasConceptScore W2014748618C2779519902 @default.
• W2014748618 hasConceptScore W2014748618C500558357 @default.
• W2014748618 hasConceptScore W2014748618C71924100 @default.
• W2014748618 hasIssue "9" @default.
• W2014748618 hasLocation W20147486181 @default.
• W2014748618 hasLocation W20147486182 @default.
• W2014748618 hasOpenAccess W2014748618 @default.
• W2014748618 hasPrimaryLocation W20147486181 @default.
• W2014748618 hasRelatedWork W1971567197 @default.
• W2014748618 hasRelatedWork W1990444464 @default.
• W2014748618 hasRelatedWork W1999753151 @default.
• W2014748618 hasRelatedWork W2004562704 @default.
• W2014748618 hasRelatedWork W2049397185 @default.
• W2014748618 hasRelatedWork W2235706673 @default.
• W2014748618 hasRelatedWork W2348895024 @default.
• W2014748618 hasRelatedWork W2349500629 @default.
• W2014748618 hasRelatedWork W2403682640 @default.
• W2014748618 hasRelatedWork W2268875648 @default.
• W2014748618 hasVolume "76" @default.
• W2014748618 isParatext "false" @default.

• next